Real-world treatment patterns and survival of patients with BRAF V600-mutated metastatic non-small cell lung cancer

•Limited real-world evidence exists on outcomes in BRAF-mutated NSCLC.•Survival in BRAF-mutated NSCLC patients may be longer than previously thought.•BRAFi/MEKi recipients had numerically longer OS versus usual care recipients.•Findings highlight potential value of BRAF/MEK-inhibiting agents as a th...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Lung cancer (Amsterdam, Netherlands) Netherlands), 2019-02, Vol.128, p.74-90
Hauptverfasser:	Horn, Leora, Bauml, Joshua, Forde, Patrick M., Davis, Keith L., Myall, Nathaniel J., Sasane, Medha, Dalal, Anand, Culver, Ken, Wozniak, Antoinette J., Baik, Christina S., Mutebi, Alex, Zhang, Pingkuan, Wakelee, Heather A., Johnson, Bruce E.
Format:	Artikel
Sprache:	eng
Schlagworte:	Adult Aged Aged, 80 and over Biomarkers, Tumor BRAF Carcinoma, Non-Small-Cell Lung - genetics Carcinoma, Non-Small-Cell Lung - mortality Carcinoma, Non-Small-Cell Lung - pathology Carcinoma, Non-Small-Cell Lung - therapy Clinical Decision-Making Combined Modality Therapy Cross-Sectional Studies Disease Management Female Humans Lung Neoplasms - genetics Lung Neoplasms - mortality Lung Neoplasms - therapy Male Middle Aged Mutation Neoplasm Metastasis Neoplasm Staging Non-small cell lung cancer Outcomes Practice Patterns, Physicians Prognosis Proto-Oncogene Proteins B-raf - genetics Real-world evidence Retrospective Studies Survival Analysis Treatment Outcome
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!